Clinical bottom line
Pediatric acute liver failure (PALF) is a rare but life-threatening condition requiring prompt recognition and multidisciplinary management in emergency and inpatient settings. Early identification of etiology, supportive care to prevent complications, and timely referral for liver transplantation evaluation are critical. Current evidence underscores the importance of standardized protocols focusing on hemodynamic stabilization, coagulopathy management, and monitoring for cerebral edema. Despite advances, prognosis remains guarded, and management strategies are largely extrapolated from limited pediatric-specific data, warranting cautious interpretation.
What the evidence shows
PALF is characterized by rapid deterioration of liver function in children without preexisting liver disease, manifesting with coagulopathy and encephalopathy (Cochran et al., 2007). Etiologies vary by age and geography, including infections, metabolic disorders, drug-induced liver injury, and autoimmune hepatitis (Mouzaki et al., 2010). Early diagnosis relies on clinical suspicion supported by laboratory markers such as elevated transaminases, prolonged prothrombin time, and rising bilirubin.
Management priorities include stabilization of airway, breathing, and circulation, correction of coagulopathy with vitamin K and plasma products as indicated, and prevention of cerebral edema through careful fluid balance and intracranial pressure monitoring (Mellinger et al., 2017). Unlike adults, pediatric patients may develop cerebral edema rapidly, necessitating vigilant neurological assessment and early neuroprotective interventions.
Supportive care encompasses correction of metabolic derangements, nutritional support, and infection surveillance. Liver transplantation remains the definitive treatment for irreversible liver failure; however, timing is challenging due to unpredictable disease progression (D’Agata et al., 1996). Multidisciplinary teams including hepatology, critical care, and transplant services improve outcomes.
Recent reviews emphasize the lack of randomized controlled trials in PALF, with most recommendations based on observational studies and expert consensus (Mouzaki et al., 2010; Mellinger et al., 2017). Advances in critical care and transplant techniques have improved survival, but morbidity remains high.
Caveats and uncertainty
The rarity and heterogeneity of PALF limit the generalizability of existing evidence. Most studies are retrospective or single-center case series, with variable definitions and outcome measures (Cochran et al., 2007). The natural history of PALF differs from adult acute liver failure, complicating extrapolation of adult data.
There is no consensus on optimal thresholds for intervention such as plasma transfusion or intracranial pressure monitoring, and the role of novel therapies remains investigational. Additionally, diagnostic delays may occur due to nonspecific early symptoms, and access to liver transplantation varies regionally.
The evidence base is evolving, and emerging biomarkers or genetic testing may refine diagnosis and prognostication in the future. Clinicians must balance aggressive supportive care with potential risks, tailoring management to individual patient factors.
How this may change practice
This evidence digest highlights the need for heightened clinical vigilance for PALF in children presenting with acute liver dysfunction. Emergency and inpatient clinicians should adopt standardized protocols emphasizing early stabilization, coagulopathy correction, and neurological monitoring.
Prompt multidisciplinary consultation and transfer to specialized centers with transplant capability are essential. Awareness of the diverse etiologies can guide targeted investigations and therapies.
Future practice may incorporate novel diagnostic tools and therapies as evidence accrues. Meanwhile, clinicians should engage in shared decision-making with families, acknowledging the uncertainty and potential for rapid clinical deterioration.